Health and Economic Outcomes Modeling Practices: A Suggested Framework

Value in Health

Volumn 1, Issue 2, 1998, Pages 131-147

  Halpern, Michael T ^a   Luce, Bryan R ^a   Brown, Ruth E ^a   Geneste, Bernard ^b  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001182423     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.1998.120131.x     Document Type: Conference Paper

References (45)

1. Glennie JL. Decision analysis: a toy or a tool for clinical practice? Can J Infect Dis 1997;8:9-10.
2. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
3. International Society of Technology Assessment in Health Care (ISTAHC) Participants. The pros and cons of modelling in economic evaluation. San Francisco, June 23-26, 1996. OHE Briefing 1997:33.
4. Sonnenberg FA, Roberts MS, Tsevar J, Wong JR, Barry M, Kent DL. Toward a peer review process for medical decision analysis models. Med Care 1994;32(Suppl 7):JS52-JS64.
5. Lilford RJ. Limitations of expert systems: intuition versus analysis. Baillieres Clin Obstet Gynaecol 1990;4:851-6.
6. Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997;6:217-27.
7. Rittenhouse B. Uses of models in economic evaluations of medicines and other health technologies. London: Office of Health Economics, 1996.
8. Sheldon TA. Problems of using modelling in the economic evaluation of health care. Health Econ 1996;5:1-11.
9. Hillner BE, Smith TJ, Desch CE. Efficacy and cost-effectiveness of autologous bone marrow trans- plantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results. JAMA 1992;267:2055-61.
10. Djulbegovic B, Hollenberg J, Woodcock TM, et al. Comparison of different treatment strategies for diffuse large cell lymphomas: a decision analysis. Med Decis Making 1991;11:1-8.
11. Kupperman M, Luce BR, McGovern B, Podrid PJ, Bigger JT, Ruskin JN. An analysis of the cost effectiveness of the implantante defibrillator. Circulation 1990;81:91-100.
12. Mandelblatt JS, Fryback DC, Weinstein MC, et al. Assessing the effectiveness of health interventions for cost-effectiveness analysis. J Gen Intern Med 1997;12:551-8.
13. Sharples LD, Briggs A, Caine N, McKenna M, Buxton M. A model for analyzing the cost of main clinical events after cardiac transplantation. Transplantation 1996;62:615-21.
14. Weinstein MC. Methodologic issues in policy modeling for cardiovascular disease. J Am Coll Cardiol 1989;14:38A-43A.
15. Simpson KN. Problems and perspectives on the use of decision-analysis models for prostate cancer. J Urol 1994;152:1888-93.
16. Doubiler P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation. Med Decis Making 1985;5(2):157-77.
17. Halpern MT, Brown RE, Drolet M, Sorensen SV, Mandell LA. Decision analysis modelling of costs and outcomes following cefepime monotherapy in Canada. Can J Infect Dis 1997;8:19-27.
18. Hurton J, Brown R, Borowitz M, Abrams K, Rothman M, Shakespeare A. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. PharmacoEconomics 1996;9(Suppl 2):8-22.
19. Butler TW. Management science/operations research projects in health care: the administrator's perspective. Health Care Manage Rev 1995;20(1):19-25.
20. Drummond MF. The future of pharmacoeconomics: bridging science and practice. Clin Ther 1996;18(5):969-78.
21. Laird NM, Mosteller F. Some statistical methods for combining experimental results. Int J Technol Assess Health Care 1990;6:5-30.
22. Stewart LA, Clarke MJ. Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group. Stat Med 1995;14(19):2057-79.
23. Koopmanschap MA, Rutten FF. The impact of indirect costs on outcomes of health care programs. Health Econ 1994;3:385-93.
24. Posnett J, Jan S. Indirect cost in economic evaluation: the opportunity cost of unpaid inputs. Health Econ 1996;5:13-23.
25. Menon D, Schubert F, Torrance GW. Canada's new guidelines for the economic evaluation of pharmaceuticals. Med Care 1996;34:DS77-86.
26. Smith TJ, Hillner BE, Desch CE. Efficacy and cost-effectiveness of cancer treatment: Rational allocation of resources based on decision analysis. J Natl Cancer Inst 1993;85:1460-74.
27. Task Force on Principles for Economic Analysis of Health Care Technology. Economic analysis of health care technology. A report on principles. Ann Intern Med 1995;123(1):61-70.
28. Hughes C, Hughes KK. N-way sensitivity analysis: a verification and stability-assessment technique for completely subjective decision analysis trees. Med Decis Making 1990;10:68-74.
29. Thornton JG, Decision analysis in obstetrics and gynaecology. Baillieres Clin Obstet Gynaecol 1990;4(4):857-66.
30. Jones J, Hunter D. Consensus methods for medical and health services research. BMJ 1995;311:376-80.
31. McMurray AR. Three decision-making aids: brainstorming, nominal group, and Delphi technique. J Nurs Staff Dev 1994;10:62-5.
32. Roche N, Durieux P. Clinical practice guidelines: from methodological to practical issues. Intensive Care Med 1994;20:593-601.
33. Carney O, McIntosh J, Worth A. The use of the Nominal Group Technique in research with community nurses. J Adv Nurs 1996;23:1024-9.
34. Horton JN. Nominal group technique. A method of decision-making by committee. Anaesthesia 1980;35:811-4.
35. Briggs A, Sculpher M. Sensitivity analysis in economic evaluation: a review of published studies. Health Econ 1995;4:355-71.
36. Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ 1994;3:95-104.
37. Piccirillo JF, Feinstein AR. Black-box mathematics and medical practice. Arch Otolaryngol Head Neck Surg 1993;119:147-55.
38. Robinson JC. Philosophical origins of the social rate of discount in cost-benefit analysis. Milbank Q 1990;68:245-65.
39. Sheldon TA. Discounting in health care decision-making: time for a change? J Public Health Med 1992;14:250-6.
40. Ganiats TG. Discounting in cost-effectiveness research. Med Decis Making 1994;14:298-300.
41. Hillman AL, Kim MS. Economic decision making in healthcare. A standard approach to discounting health outcomes. PharmacoEconomics 1995;7:198-205.
42. Revicki DA, Brown RE, Keller MR, Gonzales J, Culpepper L, Hales RE. Cost-effectiveness of newer antidepressants compared with tricyclic antide-pressants in managed care settings. J Clin Psychiatry 1997;58:47-58.
43. Luce BR. Policy implications of modeling the cost-effectiveness of health care technologies. Drug Information 1995;29:1469-75.
44. Knoebel SB. Modeling for policy decisions: potential and problems. J Am Coll Cardiol 1989;14:7A-11A.
45. Barr JT, Schumacher GE. Applying decision analysis to pharmacy management and practice decisions. Top Hosp Pharm Manage 1994;13:60-71.